sabatolimab for Myelodysplastic Syndrome (STIMULUS-MDS3 Trial)

"Unfortunately, this research study is not presently taking on any new candidates. The trial was first posted in May of 2021 and last updated in November 2022. Those searching for other clinical trials may find 1595 preleukemia studies and 345 sabatolimab trials recruiting participants."

"Although there is limited evidence for the efficacy of sabatolimab, it does have some clinical support regarding safety and was thus given a score of 2."

"Presently, there are 345 clinical investigations being conducted for sabatolimab. Of these trials 54 have reached the third phase of development while most occur in Edmonton, Alberta; however, 11 321 sites across the world offer this experimental therapy."

"According to the clinical trial sponsor, Novartis Pharmaceuticals, this medical experiment will be measuring a number of primary and secondary objectives over its duration of up to three years. The main objective includes tracking dose-limiting toxicities (DLT). Additionally, researchers are assessing event-free survival (EFS), overall response rate (ORR) after participants have achieved hematologic improvement or better, and trough serum concentration levels for MBG453."

"This investigation is no longer looking for participants. It was first posted on May 31st of 2021, and the last update to its listing occurred November 9th 2022. For individuals in search of other clinical trials, there are presently 1595 experiments recruiting patients diagnosed with preleukemia and 345 studies searching for sabatolimab candidates."

"Sabatolimab is widely used for induction chemotherapy and can treat a variety of illnesses such as refractory anemias, leukemia, myelocytic anaemia, acute dysplasia and multilineage dysplasia."